Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calaspargase pegol + Hyper-CVAD
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy regimen consists of calaspargase pegol (Asparlas) and the Hyper-CVAD multi-agent chemotherapy protocol. Calaspargase pegol is a pegylated recombinant E. coli-derived L-asparaginase enzyme that functions by depleting circulating L-asparagine, an amino acid essential for the survival of leukemic lymphoblasts which lack asparagine synthetase. The Hyper-CVAD component is an intensive chemotherapy regimen involving alternating cycles (Course A and Course B). Course A includes hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, while Course B consists of high-dose methotrexate and cytarabine. This specific combination is being investigated by the H. Lee Moffitt Cancer Center and Research Institute in a Phase 1b study to evaluate its safety and efficacy in young adults (up to age 50) with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Rituximab may also be included for patients with CD20-positive disease.
- Brand names
- Asparlas
- Other names
- Hyper-CVAD + Calaspargase PegolHyper-CVAD + AsparlasHyper CVAD-H. Lee Moffitt Cancer Center and Research Institute-acute lymphoblastic leukemia
02
Targets
TOP2A (DNA topoisomerase II)CD20 (B-lymphocyte antigen CD20)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA polymerase familyGR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on calaspargase pegol + Hyper-CVAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calaspargase pegol + Hyper-CVAD.